LIMN (Liminatus Pharma) ROC %: -302.99% (As of Mar. 2026)


What is Liminatus Pharma ROC %?

Liminatus Pharma LIMN +3.23% ROC % is -302.99% as of Mar. 2026. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Liminatus Pharma's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -302.99%.

As of today (2026-06-26), Liminatus Pharma's WACC % is 9.89%. Liminatus Pharma's ROC % is -109.75% (calculated using TTM income statement data). Liminatus Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Liminatus Pharma  (NAS:LIMN) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Liminatus Pharma's WACC % is 9.89%. Liminatus Pharma's ROC % is -109.75% (calculated using TTM income statement data). Liminatus Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Liminatus Pharma ROC % Related Terms

Liminatus Pharma ROC % Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma ROC % Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROC %
-16.42 -29.61 -18.42 -27.54

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.25 -47.70 -51.18 -232.94 -302.99

Liminatus Pharma ROC % Calculation

Liminatus Pharma's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-2.968 * ( 1 - 0% )/( (20.1 + 1.454)/ 2 )
=-2.968/10.777
=-27.54 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.409 - 4.776 - ( 0.056 - max(0, 24.749 - 5.282+0.056))
=20.1

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.513 - 8.856 - ( 0.338 - max(0, 10.298 - 0.501+0.338))
=1.454

Liminatus Pharma's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-4.404 * ( 1 - 0% )/( (1.454 + 1.453)/ 2 )
=-4.404/1.4535
=-302.99 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.513 - 8.856 - ( 0.338 - max(0, 10.298 - 0.501+0.338))
=1.454

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.79 - 1.447 - ( 1.908 - max(0, 2.889 - 2.779+1.908))
=1.453

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -302.99% mean?
Liminatus Pharma (LIMN) has a ROC % of -302.99% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Liminatus Pharma and its competitors.
Is Liminatus Pharma's ROC % too high?
Liminatus Pharma's current ROC % is -302.99%.
How does Liminatus Pharma's ROC % compare to XBIO and PCSA?
Liminatus Pharma's ROC % of -302.99% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Liminatus Pharma and its competitors. Liminatus Pharma's current ROC % is -302.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current ROC % of -302.99%. The current ROC % is -302.99%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current ROC % is -302.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.